Clover Biopharmaceuticals snaps up $230m Series C

Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing.

Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing. GL Ventures and Temasek led the round with participation from Oceanpine Capital, OrbiMed and Delos Capital.

Source: Press Release